Alaunos Therapeutics, Inc. annual report, FY2013

Business context and reporting period

The supplied filing is ZIOPHARM Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a quarterly report. This does not match the request metadata naming Alaunos Therapeutics, Inc.; verify the issuer before relying on this summary. ZIOPHARM was a development-stage oncology biopharmaceutical company, with its lead program focused on synthetic-biology cancer therapies.

Financial performance and liquidity

Revenue was collaboration funding, not product sales; the company had no approved products or product revenue. Profitability and operating margins were not meaningful given the development-stage losses. Working capital was $62.5 million, with $70.3 million in current assets and $7.8 million in current liabilities. The filing reports $11.8 million of warrant liabilities; it does not identify conventional borrowings as a material debt balance. Total liabilities were $22.4 million.

Material changes versus the prior period

• Operating expenses fell substantially following termination of palifosfamide development in soft-tissue sarcoma and a workforce reduction. R&D expense declined 49%; G&A declined 20%.
• The lower 2013 net loss also reflected a smaller noncash warrant fair-value gain ($1.2 million versus $6.1 million in 2012). The 2013 results included a $0.6 million loss on disposal of fixed assets.
• Operating cash outflow improved by $19.3 million year over year, but remained significant. The company raised approximately $53.9 million net in an October 2013 public offering, issuing 16.445 million shares including the underwriters’ option.
• Year-end shares outstanding rose to 100.2 million from 83.2 million. The filing reports 100.6 million outstanding as of February 10, 2014.

Outlook, commentary, risks and unusual items

• Management estimated existing cash would fund operations into the second quarter of 2015, but stated that additional financing would be needed for longer-term plans and that no additional capital was committed. The estimate is subject to spending, development and financing uncertainties.
• Management planned to focus internal resources on the Intrexon synthetic-biology oncology programs, seek partners for small-molecule candidates, and pursue multiple IND filings through 2015.
• Ad-RTS-IL-12 plus veledimex was in Phase 2 studies for metastatic melanoma and breast cancer. The company expected preliminary Phase 2 data in the fourth quarter of 2014 and anticipated glioma Phase 1 initiation in the first half of 2014, subject to FDA agreement. These are forward-looking plans, not reported outcomes.
• In melanoma, interim Phase 1/2 data showed stable disease or better on a per-lesion basis in 11 of 16 evaluable patients. Severe adverse events included fever, hypotension, mental-status changes and cytokine release syndrome; reported events resolved after veledimex was stopped. Breast-cancer Phase 2 data were preliminary and based on a small safety-evaluable group.
• The Phase 3 PICASSO 3 soft-tissue sarcoma trial failed its primary progression-free-survival endpoint, and that development program was terminated. Enrollment in the MATISSE Phase 3 small-cell lung cancer study was suspended after 188 patients; an interim overall-survival analysis was forecast for the second half of 2014.
• Key risks include clinical and regulatory failure, continued cash burn and potential dilution or loss of programs if financing is unavailable, reliance on Intrexon and external contractors, and intellectual-property and reimbursement uncertainty. The Intrexon agreement generally provides for 50% of product net profits or sublicense revenue to Intrexon.
• The company recorded $1.7 million of 2013 restructuring charges and $0.8 million of losses associated with office subleases, in addition to the $0.6 million fixed-asset disposal loss. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued an unqualified opinion on the financial statements and internal controls.

Important facts for investors to verify

• Confirm the filing belongs to the intended issuer: this document is for ZIOPHARM Oncology, not Alaunos Therapeutics.
• Check subsequent filings for actual cash runway, financing needs, share count and any dilution after the October 2013 offering.
• Verify later clinical results and regulatory progress for Ad-RTS-IL-12 plus veledimex, including the safety and efficacy evidence behind the preliminary reports.
• Confirm the MATISSE trial’s status and whether the planned interim analysis occurred, and review the consequences of PICASSO 3’s failure.
• Review the warrant liability, contractual obligations, Intrexon economics and any subsequent changes to collaborations or licensing plans.